Axsome Therapeutics

Research only

AXSM · Tracked drugs and regulatory events

Tracked programs

1 program

cataplexy in narcolepsy

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sec-filingwww.sec.gov

Sponsor identifies AXS-12 as reboxetine and reports a May 1, 2027 FDA target for cataplexy in narcolepsy.

Sponsor identifies reboxetine as a norepinephrine reuptake inhibitor being developed for narcolepsy.

Registry identifies a placebo-controlled AXS-12 narcolepsy study sponsored by Axsome.